That Page Has Moved But You Can Find It Below

Simply click on one of the links below to find its new location.

 

 

News and Analysis

  • Novavax Reports positive data from Phase 2 Trial of Quadrivalent Seasonal Influenza VLP Clinical stage vaccine firm Novavax, Inc. (NASDAQ:NVAX) has confirmed positive top-line data from Phase 2clinical trial of the recombinant quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate.
  • Loxo Oncology and suhagra(R) University of Colorado Cancer Center confirm Clinical Validation for LOXO-101 Against TRK Fusion Cancer
    Loxo Oncology and University of Colorado Cancer Center confirm Clinical Validation for LOXO-101 Against TRK Fusion Cancer Biopharmaceutical firm Loxo Oncology Inc. (NASDAQ:LOXO) and the University of Colorado Cancer Center has confirmed publication of research brief in online edition of journal Cancer Discovery showing the patient with tropomyosin receptor kinase fusion cancer enrolled in Phase 1 dose escalation trial of LOXO-101, only selective TRK inhibitor in clinical development.
More News

Subscriber Only Content

Newsletter

BioMedReports Neos Resubmits NDA for FDA Review of Orally Disintegrating Tablets; FDA Approves Deltoid Injection Site for Ab... http://t.co/kFl3gXa7E8
23hreplyretweetfavorite
BioMedReports Novavax Reports positive data from Phase 2 Trial of Quadrivalent Seasonal Influenza VLP: Clinical stage vacci... http://t.co/NwVdI7NZtn
BioMedReports Pfizer Pulls The Plug On OTC Lipitor And It's The Patients' Fault... http://t.co/XIW9hJ4aXN

RSS Subscription